Peter Barry, MBBS (Hons), MPhil, FRACS, Royal Marsden NHS Foundation Trust, London, UK, discusses the development of an innovative algorithm to help identify patients with post-menopausal primary ER+ HER2- breast cancer who should be prioritized for surgery earlier or could be deferred to treatment with neoadjuvant endocrine therapy. Mr Barry, a Consultant Breast Surgeon at the Royal Marsden, discusses the rationale of the study as a result of the COVID-19 pandemic, and the outcomes which were published in NPJ Breast Cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
